DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for oculocutaneous albinism type 1A — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOculocutaneous albinism type 1A maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for oculocutaneous albinism type 1a is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dopamine receptor D5 (DRD5) — DRD5 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet r5fdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8IRV · 3.1 Å · ligand Rotigotine (R5F). Experimental structure, not a prediction.
What the evidence adds up to
No drug treatment is described for oculocutaneous albinism type 1A in these abstracts. One 2025 review states that 22 genes have been identified across various forms of albinism and that emerging therapies including gene-based interventions and repurposed pharmaceuticals show promise in preclinical studies, but no specific drug, trial, or human data are given. Another 2025 scoping review notes it will map evidence on medical, surgical, and supportive therapies for visual deficits in adults with oculocutaneous albinism and ocular albinism, but its results are not yet reported. A 2023 review states plainly that to date there is no specific treatment for albinism, only palliative vision correction and sun-protection recommendations.
The 2010 paper describes Hermansky-Pudlak syndrome type 1, a related condition that includes oculocutaneous albinism alongside bleeding disorder and ceroid lipofuscinosis. In two families, four patients showed absent platelet delta-granule secretion and severe pathological platelet aggregation. Three different HPS1 gene mutations were found, one novel. No treatment was tested. The 2025 Southern African review reports a local albinism prevalence of 1 in 3900, with OCA2 and OCA3 as the commonest types, and notes that genetic causes were poorly understood by affected individuals and communities.
What is missing: no clinical trial data for any drug in oculocutaneous albinism type 1A specifically; no evidence that any repurposed pharmaceutical has been tested in humans for this condition; no funding commitment for such trials; no patient stratification strategy for future studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Klinische Pädiatrie · 2010 · 14 citations
Compound Heterozygous Mutations in 2 Siblings with Hermansky-Pudlak Syndrome Type 1 (HPS1)
AbstractBACKGROUND: Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder causing oculocutaneous albinism, bleeding disorder and ceroid lipofuscinosis. Platelets from HPS patients are characterized by the absence of dense (delta)-bodies. There are eight known human HPS GENES (HPS1-HPS8), each leading to a particular clinical HPS subtype. Restrictive lung disease, granulomatous colitis and cardiomyopathy have been described in HPS1 patients. PATIENTS: We identified HPS1 in Russian and in German siblings. All four patients show a typical HPS phenotype. The two older Russian patients demonstrate excessive bleeding after tooth extractions, recurrent epistaxis and hematomas. The two younger German patients suffer only from hematomas, so far. METHODS/RESULTS: Patients' platelets showed severe pathological agglutination/aggregation. Flow cytometry analysis demonstrated absence of platelet delta-granule secretion. Three different mutations in the HPS1 gene were found in the two families. Two mutations, p.H119delC and p.Q397delC identified in the Russian siblings had been previously described. The German siblings presented with a novel frameshift mutation (p.Q32_S33delCAGT) and the known p.Q397delC mutation. CONCLUSION: Patients with oculocutaneous albinism should be investigated for increased clinical bleeding symptoms. In case of increased bleeding symptoms, analyses of primary hemostasis should be initiated to confirm HPS. Molecular genetic investigations should be performed to distinguish the different subtypes of HPS which is important for therapy and prognosis.
Journal of Community Genetics · 2025 · 6 citations · open access
Albinism research in a Southern African setting: unique findings
AbstractResearch on oculocutaneous albinism (OCA) in the black African population has been ongoing for 52 years (1971-2023) in the Division of Human Genetics, University of the Witwatersrand, Johannesburg, South Africa. The aim of the present study was to review all the relevant published articles and focus on selected articles with unique findings. The results showed that unique findings were reported in psychosocial, cultural, epidemiological, clinical and molecular fields of study. The local prevalence of albinism was found to be 1 in 3900, higher than that reported in many other countries, although a worldwide review on prevalence showed that only 26/193 (13%) countries had published figures; the commonest types of OCA found were OCA2 and then OCA3; the high rate of skin cancer was documented; and the natural history of OCA described. Molecular studies showed that the 2.7 kb deletion mutation in the OCA2 gene is the common mutation in OCA2 locally, and further identified unique mutations in TYRP1 causing rufous albinism (OCA3) in this population. An early study found that after the birth of a child with OCA maternal-infant bonding was delayed, and only established some months later. Further research revealed that superstitions and myths surrounded the birth and the death of a person with OCA, and the belief that powerful medicines could be made from body parts, was very disturbing. Genetic causes of OCA were poorly understood by affected individuals, their relatives and communities, and genetic counselling is essential. In summary, over 30 studies were undertaken and published over a period of five decades, and many presented unique findings on this under-researched inherited condition.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
ALBINISM- A CONGENITAL DISORDER
AbstractABSTRACT Background: Albinism encompasses a group of inherited disorders characterized by reduced or absent melanin biosynthesis, affecting approximately 1 in 20,000 individuals worldwide with significant variability across geographical regions. These conditions present substantial clinical challenges and impact quality of life. Objective: This review aims to synthesize current understanding of albinism's genetic mechanisms, clinical manifestations, diagnostic approaches, available treatments, and emerging therapeutic strategies to provide a comprehensive framework for clinicians and researchers. Methods: A systematic literature search was conducted using PubMed, EMBASE, and Web of Science databases for articles published between 2000-2024, using keywords including "albinism," "oculocutaneous albinism," "ocular albinism," "melanin biosynthesis," "tyrosinase," and "albinism treatment." Studies were selected based on relevance, methodological rigor, and contribution to understanding albinism pathophysiology or treatment. Results: Recent advances have expanded understanding of albinism's genetic basis, with 22 genes now identified across various forms. Comprehensive phenotypic characterization has refined diagnostic approaches, while emerging therapies including gene-based interventions and repurposed pharmaceuticals show promise in preclinical studies. Conclusion: Albinism represents a paradigm for understanding melanin biology and neurodevelopmental visual pathways. While current management remains supportive, emerging molecular-based therapies may offer disease-modifying potential. Multidisciplinary approaches and increased awareness are essential to address both medical and psychosocial aspects of these conditions.
Open Science Framework · 2025 · 0 citations · open access
Visualizing Progress: A Scoping Review of Therapeutic Interventions for Ocular and Oculocutaneous Albinism
AbstractThis scoping review is focused on identifying and mapping the existing evidence on medical, surgical, and supportive therapies studied in adults with Oculocutaneous Albinism (OCA) and Ocular Albinism (OA). Studies published in the past 15 years will be utilized to provide an updated overview of current and emerging treatments, determine gaps in knowledge, and inform future research directions. While previous reviews have focused on both dermatologic and visual symptoms experienced by patients with albinism, our review solely centers on the efficacy of treatments for visual deficits. We believe a more thorough review focusing on improvements of visual deficits will provide a clinically relevant perspective for healthcare providers and researchers.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
ALBINISM DISEASE - CLASSIFICATION, DIAGNOSIS, SYMPTOMS AND TREATMENT MEASURES
AbstractAlbinism is a group of hereditary pathologies characterized by a violation or complete absence of skin, hair, eye pigmentation. The main symptoms of the disease are very pale skin and hair, blue or red eyes, and in some cases, vision impairment. The diagnosis of albinism is made based on the current condition of the patient, as well as genetic tests. To date, there is no specific treatment for albinism, palliative therapy (correction of vision) is used, and there are a number of recommendations for patients to behave in the sun, protect the skin and reduce the likelihood of complications
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
